Lotte Biologics set to finish 3 bioprocessing plants with 360kL capacity in Songdo by 2030

Xin Weisheng

Home > News > INDUSTRY NEWS >

05 Oct 2023
Lotte Biologics set to finish 3 bioprocessing plants with 360kL capacity in Songdo by 2030

Lotte Biologics said on Wednesday that it signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) to build three bioprocessing plants in Songdo, Incheon, by 2030.


The plants will be situated at Songdo International Business District, Block KI20 in Zone 11, and will have a total production capacity of 360,000 liters for manufacturing antibody drugs. Each plant will initially have a capacity of 120,000 liters for antibody-drug production, with the potential to add small-scale incubators and finished drug product facilities for clinical material production in the future.


Accordingly, plants 1, 2, and 3 are scheduled to be completed in 2025, 2027, and 2030, respectively. However, the company expects the total production capacity to bump up to 400,000 litres by 2034 when it will be fully operational. 


A company official stated that the construction of Plant 1 is targeted to commence in the first quarter of 2024, once all preparations for bidding and partner selection have been completed.


In particular, Lotte Biologics plans to establish a Bio-Venture Initiative which will provide incubator programs such as providing joint laboratory and research equipment and accelerating programs such as equipment-related technical support in cooperation with global equipment manufacturers. Additionally, the company will collaborate with accelerator companies to provide support for IND filing, commercialization, technology transfer strategy consulting, and other programs to connect with investors, legal, and accounting services. 


The company also stated that it will leverage its CDMO business capabilities to provide professional training programs for tenants, such as process development and CMC documentation, and establish a recruitment system in cooperation with educational institutions in Incheon to promote local employment.


Lotte Biologics further explained that it will collaborate with excellent domestic bio ventures to strengthen its R&D capabilities and diversify its domestic drug development portfolio. 


"We are pleased to build a new future for Lotte Biologics in Songdo and will continue to work tirelessly to ensure the plant construction proceeds smoothly so we can become a major player in the global CDMO market," said Lotte Biologics CEO Lee Won-jik. 


"With the construction of Lotte Biologics' plant, Songdo has firmly established itself as a global bio cluster in the spotlight of the world and will do our best to ensure the smooth construction and operation of the facility," said IFEZ Commissioner Kim Jin-yong.


(Source: KBR)

  • wechat
Recent Posts
  • Biosphere zaps germs with UV light to make biomanufacturing cheaper
    09 Jan 2025
    Biosphere zaps germs with UV light to make biomanufacturing cheaper
    Find out more
  • China's API Dominance Reshapes Global Pharmaceutical Supply Chains
    04 Dec 2024
    China's API Dominance Reshapes Global Pharmaceutical Supply Chains
    Find out more
  • From mundane to marvelous: The current and future uses of AI
    13 Nov 2024
    From mundane to marvelous: The current and future uses of AI
    Find out more

WANT TO KNOW MORE ABOUT HOW OUR

SOLUTIONS CAN HELP YOU?

Cookies
Our site uses cookies. We’d also like to set optional cookies to give you the best experience and porvide you relevant advertising. You can choose to manage your preferences or accept all cookies. You can also read our Privacy Policy and Cookie Policy for more information.